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Abstract. 
We treated a 61-year-old man with malignant pleural mesothelioma complicated by exten-
sive skeletal muscle metastases. The initial presentation included rapidly progressive weakness 
and stiffness in four extremities. The magnetic resonance image (MRI) and the computed to-
mography (CT) scan revealed disseminated symmetrical intramuscular nodular lesions. Exci-
sional biopsy was taken and pathology confirmed the presence of a biphasic metastatic meso-
thelioma by immunohistochemical (IHC) staining. The patient survived for only 3 months from 
the onset of the symptoms despite of the administration of emergency chemotherapy and opti-
mal supportive care. 
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中文摘要 
  我們報告一位 61 歲之惡性間皮癌病人併發瀰漫性的骨骼肌肉內轉移，病人初始症狀
為肌肉僵硬及無力。磁振造影及電腦斷層顯示為數眾多大小不一腫瘤分布於全身的骨骼
肌肉內，病理切片輔助螢光免疫染色法證實為轉移性惡性間皮癌。病人病況迅速惡化，
很快就變得不能移動而臥床，失去自我照顧能力且併發肺炎，最後死於呼吸衰竭。儘管
接受了化學治療，距離症狀開始，病人仍只存活了三個月。我們探討此案例骨骼肌肉內
轉移的臨床表現及意義，並回顧了過往間皮癌病人骨骼肌肉內轉移的病例報告。 
 
關鍵字: 惡性間質瘤、骨骼肌轉移、正子攝影 
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 INTRODUCTION 
Malignant mesothelioma is a neoplasm with very 
poor prognosis. It arises from mesothelial surfaces of 
the pleural cavity, peritoneal cavity, tunica vaginalis, 
or pericardium. Patients with malignant pleural meso-
thelioma typically present pulmonary symptoms. We 
are reporting on a 61-year-old man with malignant 
pleural mesothelioma with disseminated skeletal mus-
cle metastases who initially presented with muscular 
symptoms. 
 
CASE REPORT 
A 61-year-old man presented with a one-month 
history of rapidly progressive weakness and stiffness 
of the four extremities, and bilateral feet edema. He 
could not walk because of difficulties in bending his 
knees, nor could he fully stretch his elbows. He denied 
having a history of asbestos exposure. The physical 
findings were unrevealing except for diffuse muscle 
rigidity and limited range of motion. A soft tissue 
echo revealed diffuse ill-defined hypodense intra-
muscular lesions at the bilateral thigh, calf and upper 
extremities with loss of muscle fiber alignment. Sub-
sequent magnetic resonance image (MRI) demon-
strated disseminated symmetrical intramuscular nodu-
lar lesions of mild high SI on T1WI, high SI on T2WI 
with avidly enhancement distributed diffusely in the 
visible muscular structures of the pelvis, bilateral 
thighs and proximal legs (Figure 1A, axial view of 
thigh, T1WI with gadolinium contrast enhancement; 
Figure 1B and 1C, coronal view of thigh and calf). 
Excisional biopsy of a left thigh tumor was taken and 
pathology confirmed the presence of a biphasic meta-
static carcinoma (Figure 2A). By immunohistochemical  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A) Axial view of thigh, T1WI with gado-
linium contrast enhancement; (B,C) coro-
nal view of thigh and calf 
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Figure 2. (A) Pathology confirmed the presence of a biphasic metastatic carcinoma; (B) The tumor cells were also 
positive for a panel of mesothelial markers including calretinin, (C) CK 5/6, (D) D2-40 
 
 
(IHC) staining, both epithelioid and spindle cells were 
found to be positive for cytokeratin (AE1/AE3) and 
cytokeratin (CK) 7, but negative for thyroid transcrip-
tion factor-1, CDX-2, p63, and S100. In addition, the 
tumor cells were also positive for a panel of mesothe-
lial markers including calretinin (Figure 2B), CK 5/6 
(Figure 2C), and D2-40 (Figure 2D). The morpholog-
ical feature and immunophenotype both suggested the 
diagnosis of a metastatic malignant mesothelioma. A 
computed tomography (CT) scan revealed right pleu-
ral thickening, right pleural effusion, and widespread 
intramuscular metastases throughout the body, in-
cluding abdominal, paraspinal, neck, and ocular 
muscles (Figure 3A, ocular muscle; 3B, paraspinal; 
3C, neck). The pleural effusion appeared slightly 
bloody and cloudy, and there was exudation based on 
the biochemical characteristics. Although the cell 
block study failed to make a tissue diagnosis, the fea-
tures of the pleural effusion still strongly suggested a 
malignant etiology in the absence of infection. 
Nonetheless, based on these clinicopathological 
findings, the diagnosis was malignant pleural mesothe-
lioma (MPM) with disseminated skeletal muscle me-
tastases (SMM). During work-up, the patient’s condi-
tion deteriorated rapidly. He became immobile and 
bed-ridden, and also started to suffer from trismus. Af-
terwards, he received chemotherapy with pemetrexed 
plus cisplatin, the standard first-line treatment for meta- 
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Figure 3. A computed tomography (CT) scan revealed 
right pleural thickening, right pleural effusion, 
and widespread intramuscular metastases 
throughout the body, including abdominal, 
paraspinal, neck, and ocular muscles (A.  
ocular muscle; B. paraspinal; C. neck) 
static malignant mesothelioma [1]. There was neither 
objective response nor clinical improvement. Noso-
comial pneumonia developed owing to the impaired 
muscle function and inefficient sputum expectoration. 
In spite of optimal supportive care, he died of hyper-
capnic respiratory failure. The patient survived for only 
3 months from the onset of the symptoms. 
 
DISCUSSION 
Malignant mesothelioma is rare, except in large 
referral centers or epidemiologic hotspots. We treated 
a 61-year-old man with malignant mesothelioma 
complicated by extensive skeletal muscle metastases, 
whose initial presentation included rapidly progressive 
weakness and stiffness in his four extremities. The 
patient survived for 3 months from the onset of the 
symptoms despite administration of emergency chem-
otherapy and optimal supportive care. The highly ag-
gressive behavior of the tumor, combined with the 
rare manifestation causing immobility, resulted in fa-
tality in the rather short period. 
Mesothelioma is a malignant tumor that arises 
from the mesothelial surfaces, most commonly in the 
pleural cavity, but occasionally in the peritoneal cavity 
or elsewhere. Asbestos exposure constitutes the pri-
mary cause of pleural and peritoneal mesothelioma in 
humans. However, our patient claimed not to have a 
history of asbestos exposure. The public health signif-
icance of exposure from asbestos in public and private 
buildings remains controversial [2]. 
Malignant mesotheliomas are classified into three 
major subtypes: epithelioid, sarcomatoid, and biphasic 
(mixed). The widespread availability and use of im-
munohistochemistry has greatly improved the accura-
cy of diagnosis in recent years. There is no single 
marker that has sufficiently high sensitivity and speci-
ficity for malignant mesothelioma. For epithelioid 
mesothelioma, common positive immunohistochemi-
cal markers that can be used to support a diagnosis of 
malignant mesothelioma include calretinin, CK5/6, the 
Wilms' tumor-I (WT1) antigen (nuclear staining), and 
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 D2-40 (podoplanin) [3]. For sarcomatoid or biphasic 
mesothelioma, D2-40 and calretinin are the most reli-
able of the affirmative mesothelioma markers [4,5]. 
MPM is locally aggressive, with frequent invasion of 
the chest wall, mediastinum and diaphragm. Metasta-
sis to the hilar and mediastinal lymph nodes is present 
at autopsy in approximately 40%-45% of patients with 
MPM [6]. While unusual, metastases may occur. The 
reported metastatic sites include bone, central nervous 
system, lymph node, liver, lung, and soft tissue [7]. 
Skeletal muscle metastases are rare.  
Laurini et al. (1999) reported a case of MPM with 
the initial manifestation of muscle metastasis. In that 
case report, the metastatic lesion was a solitary fore-
arm mass [8]. In contrast, our patient presented with 
widespread skeletal muscle involvement at the time of 
diagnosis. Different from a readily discernible mass, 
those numerous tiny nodules of our patient were em-
bedded within muscles and thus were clinically insid-
ious. Though some nodules became palpable over thin 
muscles, such as platysma and frontalis, they were not 
perceived until quite late in the treatment. Another 
observed finding in our patient was pseudo-normality 
of limb mass, which referred to the lack of obvious 
wasting despite clinical deterioration. It was probable 
that the metastatic lesions took the space of atrophied 
muscle. Grellner et al. (1995) first reported the exist-
ence of skeletal muscle metastases in an MPM patient 
based on autopsy findings. The left temporal muscle 
and proximal limb skeletal muscles of the right upper 
arm and both thighs exhibited multiple metastases 
measuring up to 7 cm in diameter [9]. Aukema et al. 
(2009) had described a MPM patient with extensive 
soft tissue metastasis, which was detectable only by 
the whole-body [18F] fluorodeoxyglucose positron 
emission tomography with CT (FDG-PET/CT) but not 
by the conventional CT scan [10]. His general condi-
tion also deteriorated rapidly and he died three weeks 
after FDG-PET/CT. 
The rarity of skeletal muscle metastases has led to 
a number of theories, hypotheses and experimental 
models. Skeletal muscles are characterized by perma-
nent contractions. Direct consequences are high tissue 
pressure and highly variable blood flow with turbu-
lences in the microcirculation [11,12]. Further nega-
tive factors of metastatic growth in muscles include: 
local heat production due to muscular action, and pos-
sible effects of lactic acid metabolism creating a poor 
milieu for tumors, cellular and humoral immune fac-
tors in the local environment of skeletal muscle 
[13,14]. It is not known how to reconcile the discrep-
ancy between the rarity of clinically apparent SMM 
and the initial presentation of disseminated SMM in 
our patient. The “seed and soil” hypothesis may pro-
vide some insight. Paget postulated that the formation 
of metastases depends on the interaction of specially 
adapted tumor cells (seeds) and a permissive organ 
environment (soil) [15]. 
In more recent formulations of this theory, tumor 
cells must accumulate specific genetic mutations en-
dowing them with the metastatic phenotype. Once 
tumor cells acquire the ability to intravasate into the 
vasculature, they disseminate hematogenously and 
enter the parenchyma of target organs. Tumor cells 
then face diverse cellular microenvironments that 
range from permissive to hostile. Only those cells that 
are well suited to overcoming obstacles may grow, 
and only if the cells find themselves in a suitable con-
dition, will they develop into metastases [16]. The 
complex interactions between tumor cells and distant 
organs that underly disease-specific patterns of distant 
failure remain unknown. 
Haygood et al. (2012) evaluated the epidemiology 
of skeletal muscle metastases both in the literature and 
also among cases from M. D. Anderson Cancer Center 
and studied the prevalence and appearance of SMM 
among 433 patients undergoing PET/CT scans for 
non-small-cell lung cancer [17]. The most common 
source was lung cancer, and the most common site of 
involvement was the muscles of the trunk. They con-
cluded that SMM are not rare, which may be more 
apparent in a PET/CT scan than at other staging ex-
138 C. C. Chiang et al./JCRP 1(2014) 134-139
 aminations, particularly a contrast-enhanced CT scan.  
To our knowledge, we report the first case of 
MPM with the initial manifestation as disseminated 
SMM. The dismal outcome could have been attributed 
to the poor performance status secondary to the dis-
seminated SMM. The advent of more sensitive imag-
ing modalities, particularly multi-slice CT, MRI, and 
PET/CT, in the past 10-15 years, may allow more de-
tection of skeletal muscle metastases. 
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